ProQR Therapeutics (PRQR) Operating Leases (2017 - 2026)

ProQR Therapeutics (PRQR) has reported Operating Leases for 10 consecutive years, with $10.3 million the latest figure, recorded in Q1 2026.

• Quarterly Operating Leases fell 15.52% year-over-year to $10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.3 million (down 15.52% YoY) and the FY2025 annual result came in at $10.9 million, down 13.73% from the prior year.
• Operating Leases fell to $10.3 million in Q1 2026 per PRQR's latest filing, from $10.9 million in the prior quarter.
• Over the last five years, Operating Leases for PRQR reached as high as $16.6 million in Q2 2022 and fell as low as $10.3 million in Q1 2026.
• A 5-year average of $14.1 million and a median of $15.2 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases soared 93114.08% — and 2024, when it retreated 20.99%.
• Year by year, Operating Leases stood at $15.7 million in 2022, then advanced by 0.11% to $15.7 million in 2023, then fell by 19.97% to $12.6 million in 2024, then fell by 13.73% to $10.9 million in 2025, then decreased by 4.99% to $10.3 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $10.3 million, $10.9 million, and $11.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.